Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Inclusion Criteria

• Histologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease.
• Measurable disease
• Subjects 70 years of age or older; OR subjects 60-69 years of age who have one or more comorbidities.
• Meets one or more Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
• Adequate hematologic function within protocol-defined parameters.
• Adequate hepatic and renal function within protocol-defined parameters.
• ECOG performance status score of 0-2.

Exclusion Criteria

• Transformed lymphoma
• Prior treatment for follicular lymphoma.
• Central nervous system lymphoma or leptomeningeal disease.
• Currently active, clinically significant cardiovascular disease.